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Patients with non-Hodgkin’s lymphoma (NHL) 
are in need of better predictive and prognostic markers; 
this to be able to more accurately inform them in the 
clinical setting about their likely future and to better 
inform clinicians and clinician-researchers about 
treatment decisions.  One of the major impediments to 
the development of such markers in NHL has been the 
relative lack of access to well-preserved tumor tissue as 
the bulk of these cancers reside in secondary lymphoid 
organs. Procurement of tissue from affected lymph nodes 
for  molecular  risk  stratification  only  has  not  yet  been 
adopted as standard clinical practice.
One of the ways a biomarker with clinical value 
in NHL could be developed is through analysis of shed 
tumor products in plasma or serum from patients carrying 
NHLs.  This is the approach taken by He et al., 2011 in 
work reported in this issue of Oncotarget [1]. The authors 
began by developing a clever custom-array-based method 
to capture and enrich for immunoglobulin heavy chain 
gene fragments contained in sheared DNA isolated from 
NHL patients followed by use of massively parallel 
sequencing to generate a large collection of Ig sequences. 
Given that tumors usually carry one or two rearranged and 
often somatically hypermutated Ig allele, the identification 
of these tumor-specific alleles was possible.
The authors demonstrate that they could identify the 
rearranged Ig genes in primary human NHL-derived DNA 
and also in paired DNA derived from patient’s plasma.   
They went on to show that they could amplify rearranged 
Ig fragments from an additional set of NHL patients using 
just plasma as a source of DNA. To support the analysis 
of the large collection of DNA sequence tags generated 
from each sample they developed a set of novel software 
algorithms  for  Ig  gene  identification.    In  summary,  in 
the majority of patients analyzed the authors were able 
to identify the tumor-derived Ig sequences and also to 
enumerate the frequency of these in the input DNA.
One of the most important questions related to this 
innovative work is whether the approach chosen has 
identified  a  tumor  mass  marker  in  patients  with  NHL 
and whether such a features can be clinically exploited. 
To answer this question, the further development of 
this potential new biomarker will need to proceed in an 
organized and logical manner to fully explore its ultimate 
potential.  First, it will be necessary to conduct a new 
study using a larger collection of paired patient samples 
(primary tumor and paired plasma) to generate data on the 
sensitivity and specificity for plasma-derived DNA testing 
referenced against tumor DNA as the gold standard. Tests 
in large cohorts of individuals without known NHL may 
also be needed to obtain estimates on false positive calls. 
Next, and possibly within the same trial, initial 
estimates for this marker as a tumor mass marker should 
be obtained.  Here, development will be complicated 
by the absence of validated test that accurately measure 
total body tumor burden in NHL.  Nonetheless, a study 
correlating results from serial cross-sectional imaging 
with normalized numbers of tumor specific Ig-tags could 
be designed. For such a study it would be important to 
also perform the DNA test serially past completion of the 
induction chemotherapy program to obtain estimates on 
the temporal relation of CT findings and Ig-DNA levels. 
Somewhat complicating such an analysis is the current 
uncertainty as to what lymphoma cells (live cells or dead 
cells) actually contribute to and in what proportion to the 
plasma-detectable DNA.  
Future detailed clinical development of this marker 
would probably best be done within specific NHL subtypes 
and targeted to clinical situations in which current tumor 
mass assessments are semi quantitative at best. Within 
the setting of B-cell-derived NHLs, a number of clinical 
applications could be envisioned:
Diffuse large B-cell lymphoma (DLBCL), the most 
common NHL subtypes is treated relatively uniformly 
using the R-CHOP regimen as front-line therapy. 
Currently, only approximately 45-50% of patients are 
cured.  While  further  risk  stratification  using  either Oncotarget 2011; 2:  102 - 103 103 www.impactjournals.com/oncotarget
clinical tools (international prognostic index) or imaging 
tools (like PET-CTs performed during or after completion 
of planned therapy) can be accomplished, one wonders 
whether serial quantitative IgH DNA analysis as described 
here could be used to predict which patients are cured and 
which subset will relapse.
A similar scenario can be identified in mantle cell 
lymphoma  (MCL)  for  which  intensified  regimens  like 
the NORDIC regimen can achieve remission-free states 
and possible cures in a substantial subset of cases.  Could 
plasma-based IgH DNA analysis performed after the 
completion of the chemo-auto-Tx protocol be used to 
identify long term survivors?
Finally, with the recent resurgence of maintenance 
therapy approaches in follicular lymphoma (FL), could 
IgH DNA analysis be used to identify patients that may 
most benefit from such an intervention?
In summary, the elegant pilot study by He et al [1], 
has opened the door to future improved NHL care and we 
await anxiously expeditious testing of their approach in 
the clinical setting as outlined above.
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